Stock Financial Ratios

AKTX / Akari Therapeutics Plc financial ratios include Market Cap, Enterprise Value, Book Value, Quick Ratio, Current Ratio, NCAV, EBITDA, Profit Margin, Operating Margin, Return on Invested Capital (ROIC), Return on Assets (ROA), Return on Equity (ROE), Piotroski F-Score, Altman Z-Score, Beneish M Score and Kaplan-Zingales KZ-Index.

Valuation Metrics
Price2.20
Volume113,300.00
Market Cap ($M)2,779.36
Enterprise Value ($M)2,682.60
Book Value ($M)48.72
Book Value / Share0.04
Price / Book59.95
NCAV ($M)47.75
NCAV / Share0.08
Price / NCAV57.80
Income Statement (mra) ($M)
Revenue0.00
EBITDA-30.58
Net Income-45.32
Balance Sheet (mrq) ($M)
Cash & Equivalents61.43
Cash / Share0.05
Assets62.96
Liabilities16.60
Quick Ratio
Current Ratio3.30
Management Effectiveness (mra)
Return on Invested Capital (ROIC)-0.93
Return on Assets (ROA)-0.65
Return on Equity (ROE)-0.93
Identifiers and Descriptors
CUSIP00972G108
Central Index Key (CIK)1541157
Industry Groups
SIC 2834 - Pharmaceutical Preparations
Other Related CUSIPS
009726108
Share Statistics
Common Shares Outstanding1,177,693,383
Common Stock Shares Outstanding1,177,693,383
Weighted Average Number Of Diluted Shares Outstanding852,088,530
Weighted Average Number Of Shares Outstanding Basic852,088,530
Scoring Models
Piotroski F-Score2.00
Altman Z ScoreN/A
Beneish M ScoreN/A
Kaplan-Zingales KZ-IndexN/A
Cash Conversion CycleN/A
Per Share Metrics
Liabilities And Stock Equity Per Share0.00
Assets Other Non Current Per Share0.00
Cash Per Share0.05
Inventory Work In Progress Per Share0.00
Equity Per Share0.04
Property Plant And Equipment Net Per Share0.00
Additional Paid In Capital Per Share0.00
Retained Earnings Per Share-0.05
Liabilities Current Per Share0.00
Debt Per Share0.00
Deferred Income Tax Liabilities Per Share0.00
Inventory Finished Goods Per Share0.00
Liabilities Other Non Current Per Share0.00
Liabilities Per Share0.01
Intangibles Per Share0.00
Assets Per Share0.05
Goodwill Per Share0.00
Accumulated Depreciation And Depletion Per Share0.00
Cash And Equivalents Per Share0.05
Minority Interest Per Share0.00
Current Portion Of Long Term Debt Per Share0.00
Property Plant And Equipment Gross Per Share0.00
Accounts Receivable Per Share0.00
Property Plant And Equipment Per Share0.00
Inventory Raw Materials Per Share0.00
Long Term Debt Per Share0.00
Treasury Stock Per Share0.00
Assets Other Current Per Share0.00
Accounts Payable Per Share0.00
Assets Current Per Share0.05
Preferred Stock Value Outstanding Per Share0.00
Assets Non Current Per Share0.00
Inventory Per Share0.00

Peers - Pharmaceutical Preparations (2834)

Related News Stories

Alexion Ups Its Game With ALXN1210 SC

2018-02-20 seekingalpha
Alexion Pharmaceuticals (ALXN) a biopharmaceutical company which markets the blockbuster drug Soliris, is near the end of its journey to develop an even better version of Soliris called ALXN1210. Both Soliris (eculizumab) and ALXN1210 are antibodies which bind the complement protein C5, which is an effective mechanism of action in treating the rare diseases paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS). (156-0)

U.S. Biotech/Pharma Sector Daily Observations Letter: February 6, 2018

2018-02-07 seekingalpha
The broad U.S. market and the biotech sector rebounded today after hitting a key support level. Will the rebound sustain? (383-4)

Kadmon Holdings (KDMN) Jumps: Stock Rises 9.3%

2018-01-15 zacks
Kadmon Holdings, Inc. (KDMN - Free Report) was a big mover last session, as the company saw its shares more than 9% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This continues the recent uptrend for the company for the company—as the stock is now up 18.2% in the past one-month time frame. (91-2)

Stocks To Watch: Guidance Updates All Around

2018-01-13 seekingalpha
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. (668-10)

Alder BioPharmaceuticals (ALDR) Jumps: Stock Rises 15.5%

2018-01-10 zacks
Alder BioPharmaceuticals, Inc. (ALDR - Free Report) was a big mover last session, as the company saw its shares rise more than 15% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This continues the recent uptrend for the company for the company—as the stock is now up 60.27% in the past one-month time frame. (53-0)

CUSIP: 00972G108